Clinical trials: Diabete Type 1
- Condition Diabete Type 1
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00751842
- Testing
- rhGAD65
- Where
- 43 sites in United States
- Volunteers
- 331 people
- Sponsor
- Diamyd Therapeutics AB
Quality of Life, Burden, Dependency
Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life
The use by diabetes patients of real-time Continuous Glucose Monitoring (CGM) system is becoming widespread and has changed diabetic practice. Automated closed-loop (CL) insulin therapy has come of age.
- Trial name
- IMPLIQUE (NCT04939766)
- Testing
- Activation of a closed loop device in an insulin pump device with GCM
- Volunteers
- 250 people
- Sponsor
- VitalAire
Diabetes Mellitus, Type 1, Diabetes Mellitus
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Metabolic Disease
- Trial name
- NCT03345004
- Testing
- Diamyd, Vitamin D
- Where
- 18 sites in Czechia, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- Diamyd Medical AB
Diabetes Mellitus, Diabetes Type 1
ACZ885 in Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT01322321
- Testing
- ACZ885
- Where
- 10 sites in United States, Canada and 2 more
- Sponsor
- Novartis Pharmaceuticals
Diabetes Type 1
Glycemic Control and Quality of Life Evolution for Patients With T1D Using the myLoop Powered by CamAPS FX System in Combination With FreeStyle Libre 3 / 3 Plus Sensors in France
The goal of this observational study is to learn how glucose control changes over one year in people with type 1 diabetes who use the myLoop with CamAPS FX and Freestyle Libre 3 or FreeStyle Libre 3 Plus during usual care in…
- Trial name
- NCT07835685
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 220 people
- Sponsor
- mylife Diabetes Care AG
Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
The main purpose of the study is to check: Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or…
- Conditions
- Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
- Trial name
- PreTreg (NCT06688331)
- Testing
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab)
- Where
- 9 sites in Poland
- Volunteers
- 150 people
- Sponsor
- PolTREG S.A.
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00723411
- Testing
- rhGAD65
- Where
- 70 sites in Finland, France and 7 more
- Volunteers
- 334 people
- Sponsor
- Diamyd Therapeutics AB
Diabetes Type 1
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France.
- Trial name
- EPICAM-G6 (NCT07048795)
- Testing
- No Intervention: Observational Cohort
- Where
- 22 sites in France
- Volunteers
- 125 people
- Sponsor
- mylife Diabetes Care AG
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes.
- Trial name
- NCT00097071
- Testing
- insulin lispro, insulin aspart
- Where
- 52 sites in United States
- Volunteers
- 299 people
- Sponsor
- Novo Nordisk A/S